GSK3 alpha antibody
Principal name
GSK3 alpha antibody
Alternative names for GSK3 alpha antibody
Glycogen synthase kinase-3 alpha, GSK3A, GSK-3 alpha, Factor A
Ncbi ID
NP_063937.2, NP_063937, 9606, NM_019884, NP_001026837.1, NM_001031667
Available reactivities
Available hosts
Available applications
Western blot / Immunoblot (WB), Paraffin Sections (P), Enzyme Immunoassay (E), Immunocytochemistry/Immunofluorescence (ICC/IF), Immunoprecipitation (IP), Frozen Sections (C)
Background of GSK3 alpha antibody
Glycogen synthase kinase 3-alpha (GSK3A)is a multifunctional protein serine kinase implicated in the control of several regulatory proteins including glycogen synthase and transcription factors. It also plays a role in the WNT and PI3K signaling pathways.1 Under resting conditions GSK3A and its homologs are highly phosphorylated at tyr279 in the phosphorylation loop.2 Constitutive phosphorylation of this tyrosine is important for kinase activity. Dephosphorylation of tyr279 after mitogen activation is accompanied by kinase inactivation. PKA as well as PI3K-activated PKB inactivate GSK3A by phosphorylation at ser21.3 Lysophosphatidic acid primarily utilizes a PKC-dependent pathway to modulate GSK3 and certain growth factors (e.g., PDGFB), which control GSK3 mainly through PIK3-PKB, are able to regulate GSK3 through an alternative, redundant phospholipase-C-gamma-PKC pathway.4 Alzheimer disease (AD) is associated with increased production and aggregation of amyloid-beta-40 and -42 peptides into plaques. GSK3A is required for maximal production of the beta-amyloid-40 and -42 peptides generated from the amyloid precursor protein (APP) by presenilin (PSEN1)-dependent gamma-secretase cleavage.5 In vitro, lithium, a GSK3A inhibitor, blocked the production of the beta-amyloid peptides by interfering with the gamma-secretase step. In mice expressing familial AD-associated mutations in APP and PSEN1, lithium reduced the levels of beta-amyloid peptides GSK3A also phosphorylates the tau protein (MAPT), the principal component of neurofibrillary tangles in AD, and suggested that inhibition of GSK3A may offer a new therapeutic approach to AD.
General readings
1. Darrington RS et al. Distinct expression and activity of GSK-3a and GSK-3ß in prostate cancer. Int J Cancer 131:E872-83 (2012).
2. Campa VM & Kypta RM Issues associated with the use of phosphospecific antibodies to localise active and inactive pools of GSK-3 in cells. Biol Direct 6:4 (2011). WB, ICC/IF ; Human .
3. Lauing KL et al. Exogenous Activation of Wnt/ß-Catenin Signaling Attenuates Binge Alcohol-Induced Deficient Bone Fracture Healing. Alcohol Alcohol N/A:N/A (2014). Mouse .
4. Durak O et al. Ankyrin-G regulates neurogenesis and Wnt signaling by altering the subcellular localization of ß-catenin. Mol Psychiatry N/A:N/A (2014).
5. Shanmugam V et al. Whole genome sequencing reveals potential targets for therapy in patients with refractory KRAS mutated metastatic colorectal cancer. BMC Med Genomics7:36 (2014). WB .
6. Jin R et al. The metastasis suppressor NDRG1 modulates the phosphorylation and nuclear translocation of ß-catenin through mechanisms involving FRAT1 and PAK4. J Cell Sci127:3116-30 (2014). Human .
7. Rui Y et al. Activity-dependent regulation of dendritic growth and maintenance by glycogen synthase kinase 3ß. Nat Commun 4:2628 (2013).
8. Marques JM et al. CRMP2 tethers kainate receptor activity to cytoskeleton dynamics during neuronal maturation. J Neurosci 33:18298-310 (2013).
9. Ohmi K et al. Defects in the medial entorhinal cortex and dentate gyrus in the mouse model of Sanfilippo syndrome type B. PLoS One 6:e27461 (2011). IHC-Fr ; Mouse .
10. Ramirez SH et al. Inhibition of glycogen synthase kinase 3beta (GSK3beta) decreases inflammatory responses in brain endothelial cells. Am J Pathol 176:881-92 (2010). IHC-Fr ; Human .










Lane1:Hela cell lysate
Lane2:Raw264.7 cell lysate
Lane3:PC12 cell lysate

















































- Quick-Filters:
- Highly Validated (2)
Primary Antibodies
Catalog No. | Host | Iso. | Clone | Pres. | React. | Applications | |
---|---|---|---|---|---|---|---|
AP02551PU-N | GSK3 alpha antibody |
||||||
![]() |
Rabbit | Aff - Purified | Hu, Ms, Rt | ICC/IF, P, WB |
0.1 mg /
€320.00
|
||
Acris Antibodies GmbH | |||||||
![]() |
Highly validated antibody! |
||||||
AP02551PU-S | GSK3 alpha antibody |
||||||
![]() |
Rabbit | Aff - Purified | Hu, Ms, Rt | ICC/IF, P, WB |
50 µg /
€240.00
|
||
Acris Antibodies GmbH | |||||||
![]() |
Highly validated antibody! |
||||||
TA312686 | GSK3 alpha antibody |
||||||
Rabbit polyclonal GSK3a (Ab-21) antibody | |||||||
![]() |
Rabbit | IgG | Purified | Hu, Ms, Rt | E, IP, P, WB |
0.1 ml /
€335.00
|
|
OriGene Technologies, Inc. | |||||||
![]() |
|||||||
TA319231 | GSK3 alpha pSer21 antibody |
||||||
Rabbit polyclonal GSK3 Alpha phospho S21 antibody | |||||||
![]() |
Rabbit | Aff - Purified | Hu | E, WB |
0.1 mg /
€503.00
|
||
OriGene Technologies, Inc. | |||||||
TA319232 | GSK3 alpha antibody |
||||||
Rabbit polyclonal GSK3 Alpha antibody | |||||||
![]() |
Rabbit | Aff - Purified | Hu | E, WB |
0.1 mg /
€503.00
|
||
OriGene Technologies, Inc. | |||||||
TA322275 | GSK3 alpha antibody |
||||||
Anti-GSK3A (Phospho-Ser21) Rabbit Polyclonal Antibody | |||||||
![]() |
Rabbit | IgG | Purified | Hu, Ms, Rt | ICC/IF, P, WB |
0.1 ml /
€335.00
|
|
OriGene Technologies, Inc. | |||||||
![]() |
|||||||
TA322276 | GSK3 alpha antibody |
||||||
Anti-GSK3A Rabbit Polyclonal Antibody | |||||||
![]() |
Rabbit | IgG | Purified | Hu, Ms, Rt | E, P |
0.1 ml /
€335.00
|
|
OriGene Technologies, Inc. | |||||||
![]() |
|||||||
TA322277 | GSK3 alpha antibody |
||||||
Anti-GSK3A Rabbit Polyclonal Antibody | |||||||
![]() |
Rabbit | IgG | Purified | Hu, Ms, Rt | E, P |
0.1 ml /
€335.00
|
|
OriGene Technologies, Inc. | |||||||
![]() |
|||||||
TA324569 | GSK3 alpha antibody |
||||||
Rabbit polyclonal Mouse Gsk3a Antibody (C-term) | |||||||
![]() |
Rabbit | IgG | Purified | Ms | P, WB |
0.4 ml /
€410.00
|
|
OriGene Technologies, Inc. | |||||||
![]() |
|||||||
TA325026 | GSK3 alpha (C-term) antibody |
||||||
Rabbit polyclonal GSK3 alpha (GSK3A) Antibody (C-term) | |||||||
![]() |
Rabbit | Ig | Purified | Hu | P, WB |
0.4 ml /
€410.00
|
|
OriGene Technologies, Inc. | |||||||
![]() |
|||||||
TA326024 | GSK3 alpha antibody |
||||||
Rabbit Polyclonal GSK3 alpha Antibody | |||||||
![]() |
Rabbit | IgG | Purified | Hu, Ms, Rt | WB |
0.1 ml /
€335.00
|
|
OriGene Technologies, Inc. | |||||||
TA326025 | GSK3 alpha antibody |
||||||
Rabbit Polyclonal GSK3 alpha/beta Antibody | |||||||
![]() |
Rabbit | IgG | Purified | Hu, Ms, Rt | WB |
0.1 ml /
€335.00
|
|
OriGene Technologies, Inc. | |||||||
TA326026 | GSK3 alpha antibody |
||||||
Rabbit Polyclonal GSK3 alpha (Ser21) Antibody (Phospho-specific) | |||||||
![]() |
Rabbit | IgG | Purified | Hu, Ms, Rt | WB |
0.1 ml /
€335.00
|
|
OriGene Technologies, Inc. | |||||||
TA326027 | GSK3 alpha antibody |
||||||
Rabbit Polyclonal GSK3 alpha/ beta (Tyr279/216) Antibody (Phospho-specific) | |||||||
![]() |
Rabbit | IgG | Purified | Hu, Ms, Rt | WB |
0.1 ml /
€335.00
|
|
OriGene Technologies, Inc. | |||||||
AM00064PU-N | GSK3 alpha (incl. pos. control) antibody |
||||||
![]() |
Mouse | IgG1 | 10C1 | Purified | Can, Hu, Ms, Rt | WB |
0.1 mg /
€430.00
|
Acris Antibodies GmbH | |||||||
AM00065PU-N | GSK3 alpha pSer21 (incl. pos. control) antibody |
||||||
![]() |
Mouse | IgG1 | 9B8 | Purified | Can, Hu, Ms, Rt | E, WB |
0.1 mg /
€430.00
|
Acris Antibodies GmbH | |||||||
AM06171SU-N | GSK3 alpha antibody |
||||||
![]() |
Mouse | IgG1 | 9D5G1 | Ascites | Hu | ICC/IF, WB |
0.1 ml /
€400.00
|
Acris Antibodies GmbH | |||||||
![]() |
|||||||
AM06172SU-N | GSK3 alpha antibody |
||||||
![]() |
Mouse | IgG1 | 6G12C2 | Ascites | Hu | WB |
0.1 ml /
€400.00
|
Acris Antibodies GmbH | |||||||
AM08183HR-N | GSK3 alpha antibody |
||||||
![]() |
Mouse | IgG2a | SBGSK3a1 | HRP | Hu, Ms, Rt | WB |
1 ml /
€470.00
|
Acris Antibodies GmbH | |||||||
AM08183PU-N | GSK3 alpha antibody |
||||||
![]() |
Mouse | IgG2a | SBGSK3a1 | Purified | Hu, Ms, Rt | WB |
0.1 mg /
€420.00
|
Acris Antibodies GmbH |